Bispecific antibodies (bsAbs) are one of biotech’s most exciting therapeutic classes, promising the ability to bind two different targets simultaneously — unlocking new treatment possibilities in oncology, immunology, and beyond. But despite the buzz, the sobering truth from industry insiders is this: most bispecific programs collapse long before they ever hit GMP manufacturing at a […]